Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY A VIDAL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1730403072
CMS profile
811252
Location
GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$79,556.00

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $21,299.66 38
AstraZeneca Pharmaceuticals LP $15,949.67 16
Genentech, Inc. $12,092.10 13
Novartis Pharmaceuticals Corporation $9,991.71 18
Eli Lilly and Company $8,400.00 3
TerSera Therapeutics LLC $4,783.69 10
Lilly USA, LLC $2,400.00 1
PFIZER INC. $2,313.06 3
AstraZeneca UK Limited $1,995.00 1
Caris MPI, Inc. $156.31 2
Stemline Therapeutics Inc. $89.62 2
Celgene Corporation $30.51 1
Merck Sharp & Dohme LLC $22.22 1
Coherus Oncology, Inc. $17.89 1
Daiichi Sankyo Inc. $14.56 1

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY A VIDAL

NPI 1730403072 · CMS profile ID 811252

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GREGORY A VIDAL, NPI 1730403072, CMS profile ID 811252, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1730403072?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $79,556.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $95.2001/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234403555 CMS
Gilead Sciences, Inc. $200.5901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234374926 CMS
Gilead Sciences, Inc. $58.6401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234411876 CMS
Gilead Sciences, Inc. $22.5001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234499809 CMS
Gilead Sciences, Inc. $36.7401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234416317 CMS
Gilead Sciences, Inc. $19.2601/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234536108 CMS
Gilead Sciences, Inc. $851.9701/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234364157 CMS
Gilead Sciences, Inc. $489.8101/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234365999 CMS
Novartis Pharmaceuticals Corporation $99.7001/23/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200541770 CMS
PFIZER INC. $7.1501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231330818 CMS
Coherus Oncology, Inc. $17.8901/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235234533 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $88,613.24 90
PY2020 $31,416.39 37
PY2021 $33,974.68 34
PY2022 $32,625.28 53
PY2023 $42,340.24 52
PY2024 $51,297.73 72
PY2025 $79,556.00 111

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,123.48 5
PY2025 Principal investigator $3,241,032.45 262
PY2024 Recipient $3,619.00 1
PY2024 Principal investigator $3,487,689.84 128
PY2023 Recipient $1,594.25 3
PY2023 Principal investigator $2,664,891.60 124
PY2022 Principal investigator $1,790,974.97 79
PY2021 Recipient $792.10 2
PY2021 Principal investigator $283,779.40 43
PY2020 Recipient $11,229.20 2
PY2020 Principal investigator $320,975.85 71
PY2019 Recipient $10,778.50 1
PY2019 Principal investigator $367,709.52 66

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

267 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $171,801.20 12/31/2025 Non-covered Recipient Entity
West Cancer Center and Research Institute
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232924222
Principal investigator 1 Merck Sharp & Dohme LLC $3,002.44 12/31/2025 Non-covered Recipient Entity
The West Clinic, P.C.
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232925635
Principal investigator 1 Genentech, Inc. $8,252.00 12/22/2025 Non-covered Recipient Entity
The West Clinic PLLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671804
Principal investigator 1 BioNTech SE $8,806.50 12/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016630
Principal investigator 1 BioNTech SE $2,000.00 12/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016672
Principal investigator 1 BioNTech SE $1,000.00 12/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016674
Principal investigator 1 BioNTech SE $2,078.00 12/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016676
Principal investigator 1 BioNTech SE $10,000.00 12/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016678
Principal investigator 1 Genentech, Inc. $2,400.00 12/15/2025 Non-covered Recipient Entity
The West Clinic PLLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211671769
Recipient F. Hoffmann-La Roche AG $503.68 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535922
Recipient F. Hoffmann-La Roche AG $292.89 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535926
Principal investigator 1 Hoffmann-La Roche Limited $165.00 12/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672125
Principal investigator 1 Hoffmann-La Roche Limited $1,283.40 12/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672127
Principal investigator 1 BioNTech SE $5,159.70 12/11/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016626
Principal investigator 1 Hoffmann-La Roche Limited $3,148.20 12/10/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211672002
Principal investigator 1 Hoffmann-La Roche Limited $10,222.00 12/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211672008
Principal investigator 1 BioNTech SE $21,528.90 12/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016620
Principal investigator 1 Genentech, Inc. $26,136.00 12/01/2025 Non-covered Recipient Entity
The West Clinic PLLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671800
Principal investigator 1 Hoffmann-La Roche Limited $2,531.00 11/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671993
Principal investigator 1 Hoffmann-La Roche Limited $295.00 11/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671998
Principal investigator 1 BioNTech SE $910.00 11/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016640
Principal investigator 1 BioNTech SE $3,963.00 11/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016656
Principal investigator 1 BioNTech SE $473.00 11/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016664
Principal investigator 1 BioNTech SE $300.00 11/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016668
Principal investigator 1 BioNTech SE $2,100.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016642
Principal investigator 1 BioNTech SE $1,728.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016646
Principal investigator 1 BioNTech SE $455.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016648
Principal investigator 1 BioNTech SE $1,182.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016650
Principal investigator 1 BioNTech SE $3,963.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016654
Principal investigator 1 BioNTech SE $31,550.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016658
Principal investigator 1 BioNTech SE $473.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016662
Principal investigator 1 BioNTech SE $150.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016666
Principal investigator 1 BioNTech SE $8,000.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016670
Principal investigator 1 BioNTech SE $4,670.10 11/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016628
Principal investigator 1 Genentech, Inc. $10,843.00 11/13/2025 Non-covered Recipient Entity
The West Clinic PLLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671796
Principal investigator 1 Genentech, Inc. $1,000.00 11/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671730
Principal investigator 1 Genentech, Inc. $79.00 11/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671742
Principal investigator 1 Hoffmann-La Roche Limited $3,148.20 11/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671990
Principal investigator 1 BioNTech SE $14,517.90 11/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016622
Principal investigator 1 BioNTech SE $3,963.00 11/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016652
Principal investigator 1 BioNTech SE $473.00 11/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016660
Principal investigator 1 Genentech, Inc. $763.00 11/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671727
Principal investigator 1 Genentech, Inc. $18,069.00 11/05/2025 Non-covered Recipient Entity
The West Clinic PLLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671792
Principal investigator 1 Hoffmann-La Roche Limited $8,896.00 11/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672120
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016680
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016682
Principal investigator 1 Hoffmann-La Roche Limited $1,283.40 10/31/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672099
Principal investigator 1 Genentech, Inc. $6,750.00 10/30/2025 Non-covered Recipient Entity
The West Clinic PLLC
Not supplied No dispute reported 06/30/2026 1211671785
Principal investigator 1 BioNTech SE $4,309.20 10/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016634
Principal investigator 1 Hoffmann-La Roche Limited $9,963.00 10/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671981
Principal investigator 1 Hoffmann-La Roche Limited $461.00 10/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671988
Principal investigator 1 Hoffmann-La Roche Limited $5,125.00 10/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672116
Principal investigator 1 BioNTech SE $14,524.20 10/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016632
Principal investigator 1 Genentech, Inc. $14,014.00 10/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671716
Principal investigator 1 Genentech, Inc. $2,964.00 10/20/2025 Non-covered Recipient Entity
The West Clinic PLLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211671767
Principal investigator 1 Genentech, Inc. $853.00 10/20/2025 Non-covered Recipient Entity
The West Clinic PLLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671789
Recipient F. Hoffmann-La Roche AG $1,225.57 10/18/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211535930
Principal investigator 1 Hoffmann-La Roche Limited $2,668.50 10/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672109
Principal investigator 1 Hoffmann-La Roche Limited $4,516.00 10/10/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672104
Principal investigator 1 Hoffmann-La Roche Limited $11,298.00 10/10/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672112
Principal investigator 1 BioNTech SE $3,442.50 10/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016624
Principal investigator 1 Hoffmann-La Roche Limited $4,247.10 10/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671984
Principal investigator 1 BioNTech SE $5,719.98 10/03/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016636
Principal investigator 1 BioNTech SE $2,385.00 10/03/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327 No dispute reported 06/30/2026 1249016644
Principal investigator 1 Genentech, Inc. $11,214.00 10/03/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684942
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,655.52 10/02/2025 Non-covered Recipient Entity
WEST CANCER CENTER
A Phase 1b Multicentre Openlabel Modular Dose finding and Dose expansion Study to Explore the Safety Tolerability Pharmacokinetics and Anti tumour Activity of Trastuzumab Deruxtecan TDXd in Combination with Other Anticancer Agents in Patients with Metastatic HER2low Breast Cancer DESTINY Breast08 No dispute reported 06/30/2026 1185548083
Principal investigator 1 Hoffmann-La Roche Limited $9,552.00 09/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671966
Principal investigator 1 Genentech, Inc. $1,000.00 09/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671699
Principal investigator 1 Hoffmann-La Roche Limited $235.00 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671915
Principal investigator 1 Hoffmann-La Roche Limited $4,167.00 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671919
Principal investigator 1 Hoffmann-La Roche Limited $19,940.00 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671931
Principal investigator 1 Hoffmann-La Roche Limited $161.00 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671945
Principal investigator 1 Hoffmann-La Roche Limited $2,573.00 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671954
Principal investigator 1 Hoffmann-La Roche Limited $1,385.10 09/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672076
Principal investigator 1 BioNTech SE $13,131.00 09/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016774
Principal investigator 1 BioNTech SE $2,658.60 09/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016770
Principal investigator 1 Genentech, Inc. $39.00 09/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671705
Principal investigator 1 Genentech, Inc. $9,476.00 09/18/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684932
Principal investigator 1 GlaxoSmithKline, LLC. $45,303.84 09/17/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098900
Principal investigator 1 GlaxoSmithKline, LLC. $226,519.20 09/17/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192188799
Principal investigator 1 Genentech, Inc. $12,094.00 09/11/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684860
Principal investigator 1 Hoffmann-La Roche Limited $176.00 09/10/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672095
Principal investigator 1 Hoffmann-La Roche Limited $161.00 09/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671940
Principal investigator 1 BioNTech SE $11,986.20 09/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016758
Principal investigator 1 Genentech, Inc. $34,372.00 09/04/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684936
Principal investigator 1 Genentech, Inc. $9,812.00 09/04/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684938
Principal investigator 1 Genentech, Inc. $1,785.00 09/02/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684944
Principal investigator 1 BioNTech SE $92.00 09/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011596
Principal investigator 1 BioNTech SE $92.00 09/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011618
Principal investigator 1 BioNTech SE $92.00 09/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011620
Principal investigator 1 BioNTech SE $92.00 09/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011622
Principal investigator 1 Hoffmann-La Roche Limited $5,017.00 08/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671924
Principal investigator 1 Hoffmann-La Roche Limited $2,036.00 08/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671950
Principal investigator 1 Hoffmann-La Roche Limited $10,199.00 08/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671973
Principal investigator 1 Genentech, Inc. $6,020.00 08/27/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684940
Principal investigator 1 BioNTech SE $11,402.10 08/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016776
Principal investigator 1 Genentech, Inc. $20,733.00 08/22/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684946
Principal investigator 1 BioNTech SE $5,144.40 08/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016772
Principal investigator 1 BioNTech SE $3,963.00 08/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016792
Principal investigator 1 BioNTech SE $473.00 08/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016800
Principal investigator 1 BioNTech SE $100.00 08/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016808
Principal investigator 1 Genentech, Inc. $4,864.00 08/20/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684934
Principal investigator 1 Genentech, Inc. $39.00 08/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671711
Principal investigator 1 Hoffmann-La Roche Limited $560.00 08/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671969
Principal investigator 1 BioNTech SE $455.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016752
Principal investigator 1 BioNTech SE $81.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016754
Principal investigator 1 BioNTech SE $1,534.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016764
Principal investigator 1 BioNTech SE $5,473.80 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016766
Principal investigator 1 BioNTech SE $1,423.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016780
Principal investigator 1 BioNTech SE $1,218.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016782
Principal investigator 1 BioNTech SE $255.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016784
Principal investigator 1 BioNTech SE $74.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016786
Principal investigator 1 BioNTech SE $4,420.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016790
Principal investigator 1 BioNTech SE $1,756.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016798
Principal investigator 1 BioNTech SE $900.00 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016806
Principal investigator 1 BioNTech SE $5,820.06 08/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016812
Principal investigator 1 Hoffmann-La Roche Limited $2,623.50 08/13/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671935
Principal investigator 1 Hoffmann-La Roche Limited $502.00 08/13/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672091
Principal investigator 1 BioNTech SE $3,899.70 08/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016760
Principal investigator 1 Eli Lilly and Company $21,018.00 08/06/2025 Non-covered Recipient Entity
THE WEST CLINIC
Not supplied No dispute reported 06/30/2026 1187891114
Principal investigator 1 Hoffmann-La Roche Limited $14,391.00 08/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671910
Principal investigator 1 Hoffmann-La Roche Limited $1,195.00 08/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671958
Principal investigator 1 GlaxoSmithKline, LLC. $47,177.52 08/05/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098892
Principal investigator 1 Genentech, Inc. $1,665.00 08/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671680
Principal investigator 1 Hoffmann-La Roche Limited $1,283.40 08/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672070
Principal investigator 1 BioNTech SE $14,535.90 07/31/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016778
Principal investigator 1 Genentech, Inc. $741.00 07/29/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684858
Principal investigator 1 Genentech, Inc. $9,627.00 07/25/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684928
Principal investigator 1 Genentech, Inc. $1,149.00 07/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671690
Principal investigator 1 Hoffmann-La Roche Limited $192.00 07/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672073
Principal investigator 1 BioNTech SE $3,963.00 07/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016794
Principal investigator 1 BioNTech SE $473.00 07/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016802
Principal investigator 1 BioNTech SE $200.00 07/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016810
Principal investigator 1 Genentech, Inc. $9,235.00 07/21/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684930
Principal investigator 1 GlaxoSmithKline, LLC. $70,766.28 07/20/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098915
Principal investigator 1 BioNTech SE $10,656.00 07/17/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016768
Principal investigator 1 Genentech, Inc. $169.00 07/17/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671695
Principal investigator 1 Genentech, Inc. $241.00 07/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684924
Principal investigator 1 Hoffmann-La Roche Limited $4,821.30 07/11/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671961
Principal investigator 1 Hoffmann-La Roche Limited $8,459.00 07/11/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672081
Principal investigator 1 BioNTech SE $8,820.90 07/10/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016762
Principal investigator 1 Genentech, Inc. $6,809.00 07/10/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684856
Principal investigator 1 Genentech, Inc. $6,750.00 07/09/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Not supplied No dispute reported 06/30/2026 1211684922
Principal investigator 1 Hoffmann-La Roche Limited $60.00 07/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671928
Principal investigator 1 Hoffmann-La Roche Limited $11,084.00 07/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671975
Principal investigator 1 Hoffmann-La Roche Limited $1,474.20 07/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672085
Principal investigator 1 Genentech, Inc. $17,792.00 07/07/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684926
Principal investigator 1 BioNTech SE $11,297.70 07/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016756
Principal investigator 1 BioNTech SE $3,963.00 07/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016788
Principal investigator 1 BioNTech SE $473.00 07/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016796
Principal investigator 1 BioNTech SE $800.00 07/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016804
Principal investigator 1 Hoffmann-La Roche Limited $14,327.10 07/02/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671907
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011594
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
The West Clinic, P.C. d/b/a West Cancer Center
BNT327-02 No dispute reported 06/30/2026 1249011612
Principal investigator 1 BioNTech SE $14,368.50 06/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016724
Principal investigator 1 Hoffmann-La Roche Limited $641.00 06/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672031
Principal investigator 1 BioNTech SE $10,912.50 06/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016722
Principal investigator 1 BioNTech SE $300.00 06/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016748
Principal investigator 1 BioNTech SE $11,040.06 06/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016750
Principal investigator 1 GlaxoSmithKline, LLC. $35,383.14 06/18/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098883
Principal investigator 1 GlaxoSmithKline, LLC. $226,519.20 06/18/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098889
Principal investigator 1 AstraZeneca UK Limited $14,788.80 06/11/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
A Phase 1b Multicentre Openlabel Modular Dose finding and Dose expansion Study to Explore the Safety Tolerability Pharmacokinetics and Anti tumour Activity of Trastuzumab Deruxtecan TDXd in Combination with Other Anticancer Agents in Patients with Metastatic HER2low Breast Cancer DESTINY Breast08 No dispute reported 06/30/2026 1185548085
Principal investigator 1 Genentech, Inc. $612.00 06/09/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684902
Principal investigator 1 Hoffmann-La Roche Limited $54.00 06/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672027
Principal investigator 1 Hoffmann-La Roche Limited $2,101.00 06/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671878
Principal investigator 1 Hoffmann-La Roche Limited $54.00 06/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672035
Principal investigator 1 Hoffmann-La Roche Limited $261.00 06/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672062
Principal investigator 1 Daiichi Sankyo Inc. $4,099.80 06/02/2025 Non-covered Recipient Entity
West Cancer Center And Research Institute-East Campus
DS8201-A-U301 No dispute reported 06/30/2026 1223390904
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $32,926.25 05/30/2025 Non-covered Recipient Entity
THE WEST CLINIC, PC
IST FACT-2 (WEST CLINIC) DR. VIDAL No dispute reported 06/30/2026 1251754136
Principal investigator 1 Genentech, Inc. $5,676.00 05/28/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684898
Principal investigator 1 Hoffmann-La Roche Limited $3,257.10 05/28/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672060
Principal investigator 1 BioNTech SE $7,119.00 05/27/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016720
Principal investigator 1 Genentech, Inc. $9,228.00 05/27/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684900
Principal investigator 1 BioNTech SE $3,963.00 05/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016740
Principal investigator 1 BioNTech SE $473.00 05/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016742
Principal investigator 1 BioNTech SE $100.00 05/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016744
Principal investigator 1 BioNTech SE $5,520.00 05/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016746
Principal investigator 1 Genentech, Inc. $1,482.00 05/21/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684842
Principal investigator 1 Hoffmann-La Roche Limited $2,049.30 05/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671874
Principal investigator 1 Hoffmann-La Roche Limited $474.00 05/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672045
Principal investigator 1 Hoffmann-La Roche Limited $6,395.40 05/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672049
Principal investigator 1 Hoffmann-La Roche Limited $10,649.00 05/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672053
Principal investigator 1 Genentech, Inc. $2,090.00 05/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671631
Principal investigator 1 Genentech, Inc. $14,482.00 05/19/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684910
Principal investigator 1 BioNTech SE $5,492.70 05/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016718
Principal investigator 1 Hoffmann-La Roche Limited $19,341.00 05/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671903
Principal investigator 1 Genentech, Inc. $33,034.00 05/09/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684908
Principal investigator 1 Hoffmann-La Roche Limited $308.70 05/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672041
Principal investigator 1 Hoffmann-La Roche Limited $3,949.20 05/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672066
Principal investigator 1 BioNTech SE $1,623.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016726
Principal investigator 1 BioNTech SE $6,303.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016728
Principal investigator 1 BioNTech SE $2,228.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016730
Principal investigator 1 BioNTech SE $2,207.56 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016732
Principal investigator 1 BioNTech SE $293.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016734
Principal investigator 1 BioNTech SE $3,963.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016736
Principal investigator 1 BioNTech SE $473.00 05/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016738
Recipient F. Hoffmann-La Roche AG $3,050.67 05/08/2025 Covered Recipient Physician A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment No dispute reported 06/30/2026 1211535914
Principal investigator 1 Genentech, Inc. $8,420.00 05/07/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684912
Principal investigator 1 Hoffmann-La Roche Limited $9,701.00 05/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671882
Principal investigator 1 Hoffmann-La Roche Limited $2,327.00 05/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671891
Principal investigator 1 Genentech, Inc. $1,087.00 05/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671619
Principal investigator 1 BioNTech SE $7,219.80 04/28/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016716
Principal investigator 1 Genentech, Inc. $9,947.00 04/25/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684918
Principal investigator 1 Hoffmann-La Roche Limited $2,049.30 04/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671896
Principal investigator 1 Hoffmann-La Roche Limited $2,101.00 04/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671886
Principal investigator 1 BioNTech SE $5,593.50 04/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016714
Principal investigator 1 Genentech, Inc. $1,000.00 04/15/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684852
Principal investigator 1 Genentech, Inc. $1,359.00 04/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684846
Principal investigator 1 Genentech, Inc. $1,200.00 04/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684848
Principal investigator 1 Genentech, Inc. $11,688.00 04/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684916
Principal investigator 1 Genentech, Inc. $1,422.00 04/11/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684850
Principal investigator 1 Genentech, Inc. $1,717.00 04/11/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684854
Principal investigator 1 Genentech, Inc. $2,964.00 04/09/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211684844
Principal investigator 1 BioNTech SE $4,734.00 04/08/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016712
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,450.00 04/04/2025 Non-covered Recipient Entity
ONEONCOLOGY
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185548087
Principal investigator 1 Genentech, Inc. $563.00 04/02/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684920
Principal investigator 1 BioNTech SE $4,790.70 04/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016710
Principal investigator 1 Genentech, Inc. $724.00 04/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671611
Recipient F. Hoffmann-La Roche AG $3,050.67 03/31/2025 Covered Recipient Physician A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment No dispute reported 06/30/2026 1211535918
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,477.62 03/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185548079
Principal investigator 1 Hoffmann-La Roche Limited $148.00 03/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671836
Principal investigator 1 Hoffmann-La Roche Limited $2,188.00 03/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671841
Principal investigator 1 Hoffmann-La Roche Limited $507.00 03/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671846
Principal investigator 1 BioNTech SE $7,119.00 03/25/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016700
Principal investigator 1 BioNTech SE $5,492.70 03/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016698
Principal investigator 1 BioNTech SE $3,680.00 03/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016708
Principal investigator 1 Hoffmann-La Roche Limited $3,079.80 03/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671832
Principal investigator 1 Genentech, Inc. $4,815.00 03/18/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684914
Principal investigator 1 Genentech, Inc. $6,750.00 03/17/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Not supplied No dispute reported 06/30/2026 1211684896
Principal investigator 1 BioNTech SE $7,877.70 03/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016696
Principal investigator 1 Genentech, Inc. $14,976.00 03/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211684906
Principal investigator 1 Hoffmann-La Roche Limited $60.00 03/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671858
Principal investigator 1 Hoffmann-La Roche Limited $292.50 03/12/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672023
Principal investigator 1 BioNTech SE $5,356.80 03/11/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016694
Principal investigator 1 Eli Lilly and Company $2,932.00 03/10/2025 Non-covered Recipient Entity
THE WEST CLINIC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891908
Principal investigator 1 BioNTech SE $2,549.70 03/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016692
Principal investigator 1 Hoffmann-La Roche Limited $422.00 02/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671808
Principal investigator 1 Hoffmann-La Roche Limited $21,094.00 02/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671863
Principal investigator 1 Hoffmann-La Roche Limited $674.00 02/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671869
Principal investigator 1 Hoffmann-La Roche Limited $2,427.00 02/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671819
Principal investigator 1 Hoffmann-La Roche Limited $2,037.60 02/19/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671828
Principal investigator 1 BioNTech SE $24,798.60 02/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016690
Principal investigator 1 Genentech, Inc. $8,275.00 02/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671635
Principal investigator 1 BioNTech SE $6,936.30 02/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016688
Principal investigator 1 Hoffmann-La Roche Limited $13,720.00 02/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672019
Principal investigator 1 Genentech, Inc. $1,234.00 02/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671582
Principal investigator 1 Genentech, Inc. $18,512.00 02/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671638
Principal investigator 1 Hoffmann-La Roche Limited $9,147.00 01/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671815
Principal investigator 1 Hoffmann-La Roche Limited $490.00 01/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671823
Principal investigator 1 Hoffmann-La Roche Limited $3,050.00 01/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671855
Principal investigator 1 Hoffmann-La Roche Limited $32,333.00 01/29/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671866
Principal investigator 1 Eli Lilly and Company $71,692.00 01/28/2025 Non-covered Recipient Entity
THE WEST CLINIC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891574
Principal investigator 1 Hoffmann-La Roche Limited $1,030.50 01/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671811
Principal investigator 1 Hoffmann-La Roche Limited $3,030.00 01/22/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
MORPHEUS TNBC No dispute reported 06/30/2026 1211672015
Principal investigator 1 Genentech, Inc. $1,728.00 01/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211671594
Principal investigator 1 Genentech, Inc. $5,045.00 01/21/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211684904
Principal investigator 1 BioNTech SE $4,977.90 01/17/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016686
Principal investigator 1 Genentech, Inc. $6,750.00 01/16/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Not supplied No dispute reported 06/30/2026 1211684894
Principal investigator 1 Genentech, Inc. $563.00 01/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211671642
Principal investigator 1 Hoffmann-La Roche Limited $2,063.70 01/13/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLCWEST CLINIC RESEARCH DEPARTMENT
Morpheus Breast Cancer No dispute reported 06/30/2026 1211671852
Principal investigator 1 BioNTech SE $1,816.00 01/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016702
Principal investigator 1 BioNTech SE $122.00 01/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016704
Principal investigator 1 BioNTech SE $1,013.00 01/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016706
Principal investigator 1 GlaxoSmithKline, LLC. $181,215.36 01/09/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192188803
Principal investigator 1 GlaxoSmithKline, LLC. $770,165.25 01/08/2025 Non-covered Recipient Entity
WEST CANCER CENTER
0000000000000000000000000000000000000000000000000000000000000000214360 No dispute reported 06/30/2026 1192098906
Principal investigator 1 BioNTech SE $8,016.30 01/07/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
BNT327-02 No dispute reported 06/30/2026 1249016684
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,319.87 01/03/2025 Non-covered Recipient Entity
WEST CANCER CENTER
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185548077